Politics Science And Cancer

A Nobel Prize–winning cancer biologist, leader of major scientific institutions, and scientific adviser to President Obama reflects on his remarkable career. A PhD candidate in English literature at Harvard University, Harold Varmus discovered he was drawn instead to medicine and eventually found himself at the forefront of cancer research at the University of California, San Francisco. In this “timely memoir of a remarkable career” (American Scientist), Varmus considers a life’s work that thus far includes not only the groundbreaking research that won him a Nobel Prize but also six years as the director of the National Institutes of Health; his current position as the president of the Memorial Sloan-Kettering Cancer Center; and his important, continuing work as scientific adviser to President Obama. From this truly unique perspective, Varmus shares his experiences from the trenches of politicized battlegrounds ranging from budget fights to stem cell research, global health to science publishing.

This book examines the politics of cancer, explains how our government is intrinsically tied to cancer research efforts, and documents how major political actors make cancer policy and are influenced in their decision making by political, social, scientific, and economic variables. Is whether we contract cancer—and whether we survive the disease, if we get it—largely just a result of good versus bad luck, or are these outcomes regarding cancer tied to the policies and actions of our federal government? Cancer-treating drug development and approval is overseen by the U.S. Food and Drug Administration, billions of dollars of federal money are devoted towards cancer research, and exposure of citizens to potentially cancer-causing environments or chemicals is regulated by the Environmental Protection Agency. Additionally, all of these factors can be affected by the political motivations of our most powerful politicians. The Politics of Cancer: Malignant Indifference analyzes the policy environment of cancer in America: the actors, the political institutions, the money, and the disease itself, identifying how haphazard U.S. government policy toward cancer research has been and how the president, Congress, government bureaucracies, and even the cancer industry have failed to meet timelines and make the expected discoveries. Whitman Cobb examines funding for the National Cancer Institute and the roles of the executive, Congress, policy entrepreneurs, and the bureaucracy as well as that of the state of cancer science. She argues that despite the so-called "war on cancer," no strategic, comprehensive government policy has been imposed—leading to an indecisive cancer policy that has significantly impeded cancer research. Written from a political science perspective, the book enables readers to gain insight into the realities of science policy and the ways in which the federal government is both the source of funding for much of cancer research and often deficient in setting comprehensive and consistent anti-cancer policy. Readers will also come to understand how Congress, the president, the bureaucracy, and the cancer industry all share responsibility for the current state of cancer policy confusion and consider whether pharmaceutical companies, for-profit cancer treatment hospitals, and interest groups like the American Cancer Society have a personal incentive to keep the fight alive.

This book examines the politics of cancer, explains how our government is intrinsically tied to cancer research efforts, and documents how major political actors make cancer policy and are influenced in their decision making by political, social, scientific, and economic variables. Is whether we contract cancer—and whether we survive the disease, if we get it—largely just a result of good versus bad luck, or are these outcomes regarding cancer tied to the policies and actions of our federal government? Cancer-treating drug development and approval is overseen by the U.S. Food and Drug Administration, billions of dollars of federal money are devoted towards cancer research, and exposure of citizens to potentially cancer-causing environments or chemicals is regulated by the Environmental Protection Agency. Additionally, all of these factors can be affected by the political motivations of our most powerful politicians. The Politics of Cancer: Malignant Indifference analyzes the policy environment of cancer in America: the actors, the political institutions, the money, and the disease itself, identifying how haphazard U.S. government policy toward cancer research has been and how the president, Congress, government bureaucracies, and even the cancer industry have failed to meet timelines and make the expected discoveries. Whitman Cobb examines funding for the National Cancer Institute and the roles of the executive, Congress, policy entrepreneurs, and the bureaucracy as well as that of the state of cancer science. She argues that despite the so-called "war on cancer," no strategic, comprehensive government policy has been imposed—leading to an indecisive cancer policy that has significantly impeded cancer research. Written from a political science perspective, the book enables readers to gain insight into the realities of science policy and the ways in which the federal government is both the source of funding for much of cancer research and often deficient in setting comprehensive and consistent anti-cancer policy. Readers will also come to understand how Congress, the president, the bureaucracy, and the cancer industry all share responsibility for the current state of cancer policy confusion and consider whether pharmaceutical companies, for-profit cancer treatment hospitals, and interest groups like the American Cancer Society have a personal incentive to keep the fight alive.

Mark Rushefsky confronts head-on the controversies surrounding federal cancer policy, within the context, however, of a balanced view of the politics and science involved. From 1976 to 1984, federal agencies such as the Consumer Product Safety Commission, the Environmental Protection Agency, the Food and Drug Administration, the Occupational Safety and Health Administration issued guidelines regulating public exposure to chemical carcinogens. These policies have engendered controversy and undergone numerous changes. Some of these are based on new scientific developments, others on new political developments. Making Cancer Policy analyzes the guidelines issued by these agencies in terms of their scientific and political environment. It addresses the issues of uncertainty in the scientific foundation of cancer policy, scientific controversies, the mixing of science and politics, and the political uses of science. This book shows just how "political" science can be.

"The Politics of Cancer Revisited," by internationally renowned authority on cancer causes and preventions, Samuel S. Epstein, M.D., backed by meticulous documentation, charges that the cancer establishment remains myopically fixated on damage control--diagnosis and treatment, and basic genetic research with, not always benign, indifference to cancer prevention research and failure of outreach to Congress, regulatory agencies, and the public with scientific information on unwitting exposures to a wide range of avoidable causes of cancer. The National Cancer Institute (NCI) and the American Cancer Society (ACS) are also accused of pervasive conflicts of interest, particularly with the cancer drug industry.

At no time in U.S. history has there been a more effective challenge to medical expertise and authority than that mounted by the contemporary Laetrile movement. The efficacy of Laetrile has been debated for over twenty-five years, but despite vigorous opposition from the medical community, support for the purported cancer treatment continues to gro

Written by a highly regarded historian of science, this meticulouly researched, eminently fair, and very provocative book attempts to answer the question: Why, given all the time and money spent on cancer research, can't we get consistent answers to the most fundamental questions about prevention and treatment?